CAPD 17 Balance Peritoneal Dialysis Solution (Import Name: Balance 1.5% glucose, 1.25 mmol Calcium)

Adult administration

Generally, for adults, 1.5 to 2.5 L should be infused into the peritoneal cavity and drained after a retention period of 4 to 8 hours, performed 3 to 5 times a day.

This drug is a dialysis solution used for peritoneal dialysis to remove waste and excess fluid from the body through the peritoneum. When using this drug, stopping peritoneal dialysis prematurely can be life-threatening, so it should not be discontinued if no other renal replacement therapy is prepared. Patients with diaphragm defects, severe abdominal wounds or inflammation, or severe peritoneal adhesions may experience problems such as shortness of breath or decreased dialysis efficiency when using this drug, and thus it should not be administered. Additionally, patients with hemorrhagic diathesis or suspected lactic acidosis, severe hypokalemia, or hypocalcemia should not be treated with this drug. Patients recovering from abdominal surgery, those with inflammatory bowel disease, abdominal fistula, intra-abdominal tumors, or hernia are also advised against the use of this drug. Patients with sepsis, severe lung disease, severe lipid metabolism disorders, or those who cannot physically or mentally perform peritoneal dialysis should be monitored carefully. Patients taking digitalis preparations must regularly check their serum potassium levels, and those suspected of glucose metabolism disorders should periodically monitor their blood glucose levels. Patients with lumbar disorders, those using colostomy, patients on diuretics, severely ventilated patients, severely obese patients, immunocompromised patients, and those with allergies to antibiotics should also be administered this drug carefully. Pregnant women, patients with peritonitis, or those with hyperparathyroidism should carefully monitor serum calcium levels during administration, and additional treatment may be required if necessary. Some adverse reactions may occur at the injection site when using this drug, such as abdominal pain, bleeding, peritonitis, or inflammation around the catheter. In addition, a variety of adverse reactions such as nausea, abdominal pain, diarrhea, constipation, hemorrhoids, vomiting, anorexia, abdominal distension, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, and metabolic acidosis may occur, requiring caution. During peritoneal dialysis, multiple indicators like weight, nutritional status, blood electrolytes, acid-base balance, and blood glucose should be regularly monitored, and aseptic techniques are essential to prevent peritonitis. The peritoneal dialysis solution should be used as provided in the container, and should not be used if the container is damaged or if the solution is cloudy. Use only for peritoneal dialysis and not for injection. The solution should be pre-warmed to body temperature before use, and the dosage for children should be adjusted based on their age and weight. Excessive dosing may cause dehydration, electrolyte imbalances, and hyperglycemia, so the infusion rate and dosage must be strictly managed. Pregnant or breastfeeding women should use this drug only when the therapeutic benefits outweigh the risks, as its safety has not been established. Lastly, this drug is known not to affect driving or machine operation ability.

Serious side effects

Sepsis (related to the peritoneal dialysis process)

Mild side effects

Abdominal pain, bleeding, peritonitis (abdominal pain, cloudy discharge, sometimes accompanied by fever), inflammation around the abdominal catheter (redness, secretion), subcutaneous erythema in case of catheter damage or drainage difficulties, nausea, abdominal pain, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal bloating, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis,

This drug may lose its effectiveness if stored at temperatures below 4 degrees Celsius, so it must be stored at temperatures above 4 degrees Celsius. Avoid refrigeration and maintain appropriate temperatures to preserve the drug's quality.

Appearance

A-shaped solution A (left) and solution B (right), a colorless and transparent liquid divided into two solutions

Package unit

100 bags/box [2,000 mL/bag X 1 piece], 400 bags/box [2,000 mL/bag X 4 pieces]